Filing Details
- Accession Number:
- 0001209191-17-064325
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-12-07 09:57:51
- Reporting Period:
- 2017-11-03
- Accepted Time:
- 2017-12-07 09:57:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1674416 | Crispr Therapeutics Ag | CRSP | Pharmaceutical Preparations (2834) | DE |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 816284 | Celgene Corp /De/ | 86 Morris Avenue Summit NJ 07901 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2017-11-03 | 22,759 | $19.10 | 4,812,221 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-11-06 | 79,327 | $18.89 | 4,732,894 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-11-07 | 23,000 | $18.54 | 4,709,894 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-11-08 | 16,875 | $18.06 | 4,693,019 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-11-09 | 20,000 | $17.08 | 4,673,019 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-11-10 | 10,000 | $17.28 | 4,663,019 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-11-13 | 65,093 | $17.76 | 4,597,926 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-11-14 | 14,907 | $17.19 | 4,583,019 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-11-15 | 15,000 | $17.67 | 4,568,019 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-11-16 | 105,000 | $18.39 | 4,463,019 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-11-17 | 51,282 | $18.44 | 4,411,737 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-11-20 | 158,718 | $19.02 | 4,253,019 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2018-11-21 | 80,000 | $19.25 | 4,173,019 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-11-22 | 256,000 | $19.76 | 3,917,019 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-11-24 | 26,010 | $20.00 | 3,891,009 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-11-27 | 27,990 | $19.75 | 3,863,019 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-11-28 | 5,080 | $19.22 | 3,857,939 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-11-29 | 4,263 | $19.25 | 3,853,676 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-11-30 | 12,666 | $19.04 | 3,841,010 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-12-01 | 87,991 | $19.10 | 3,753,019 | No | 4 | S | Indirect | See explanation of responses |
| Common Stock | Disposition | 2017-12-04 | 30,485 | $19.47 | 3,722,534 | No | 4 | S | Indirect | See explanation of responses |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
| No | 4 | S | Indirect | See explanation of responses |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4
- These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.
- Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Billionaire Hedge Funds
